EP Wealth Advisors LLC Makes New $7.96 Million Investment in Thermo Fisher Scientific Inc. $TMO

EP Wealth Advisors LLC bought a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 15,882 shares of the medical research company’s stock, valued at approximately $7,963,000.

A number of other hedge funds have also modified their holdings of the stock. Legacy Wealth Managment LLC ID boosted its position in Thermo Fisher Scientific by 78.6% during the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 22 shares during the last quarter. Kilter Group LLC purchased a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth about $25,000. Allied Private Wealth LLC acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at about $26,000. High Note Wealth LLC grew its stake in shares of Thermo Fisher Scientific by 170.6% in the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after buying an additional 29 shares in the last quarter. Finally, Swiss RE Ltd. acquired a new position in Thermo Fisher Scientific in the fourth quarter worth approximately $28,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have issued reports on TMO shares. KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Weiss Ratings upgraded shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, July 14th. Robert W. Baird reduced their price objective on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Finally, Sanford C. Bernstein started coverage on Thermo Fisher Scientific in a report on Friday, June 26th. They set a “market perform” rating and a $520.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average price target of $619.41.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 4,608 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $586.12, for a total value of $2,700,840.96. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the transaction, the chief accounting officer owned 2,966 shares of the company’s stock, valued at approximately $1,734,546.46. This trade represents a 12.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 63,493 shares of company stock valued at $37,657,681 in the last quarter. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Trading Up 0.2%

NYSE:TMO opened at $629.02 on Friday. The company’s 50 day moving average is $542.53 and its 200-day moving average is $509.70. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $643.99. The firm has a market cap of $232.58 billion, a price-to-earnings ratio of 33.84, a P/E/G ratio of 2.56 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same period in the prior year, the firm earned $4.28 EPS. Thermo Fisher Scientific’s quarterly revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is 10.11%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.